Ezzat, Shahira MMerghany, Rana MAbdel Baki, Passent MAbdelrahim, Nariman AliOsman, Sohaila MSalem, Mohamed APeña-Corona, Sheila ICortés, HernánKiyekbayeva, LashynLeyva-Gómez, GerardoSharifi-Rad, JavadCalina, Daniela2024-04-142024-04-142024-04https://doi.org/10.1002/mnfr.202400063http://repository.msa.edu.eg/xmlui/handle/123456789/5935Phenethyl isothiocyanate (PEITC), a compound derived from cruciferous vegetables, has garnered attention for its anticancer properties. This review synthesizes existing research on PEITC, focusing on its mechanisms of action in combatting cancer. PEITC has been found to be effective against various cancer types, such as breast, prostate, lung, colon, and pancreatic cancers. Its anticancer activities are mediated through several mechanisms, including the induction of apoptosis (programmed cell death), inhibition of cell proliferation, suppression of angiogenesis (formation of new blood vessels that feed tumors), and reduction of metastasis (spread of cancer cells to new areas). PEITC targets crucial cellular signaling pathways involved in cancer progression, notably the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB), Protein Kinase B (Akt), and Mitogen-Activated Protein Kinase (MAPK) pathways. These findings suggest PEITC's potential as a therapeutic agent against cancer. However, further research is necessary to determine the optimal dosage, understand its bioavailability, and assess potential side effects. This will be crucial for developing PEITC-based treatments that are both effective and safe for clinical use in cancer therapy.enArticlehttps://doi.org/10.1002/mnfr.202400063